We would love for you to become a part of our community. Join our Discord to connect with us and other members!

Ticker
LONN.SW

Price
554.40
Stock movement up
+6.60 (1.20%)
Company name
Lonza Group AG
Exchange
(SW
,
Currency
CHF
)
Sector
Healthcare >
Diagnostics & Research
Market cap
39.98B
Ent value
47.05B
Price/Sales
3.59
Price/Book
4.25
Div yield
-
Div growth
-
Growth years
-
FCF payout
-147.26%
Trailing P/E
23.26
Forward P/E
33.76
PEG
-
EPS growth
3.48%
1 year return
49.60%
3 year return
-4.98%
5 year return
8.58%
10 year return
17.33%
Last updated: 2025-01-18

iO Charts is a Seeking Alpha partner

iO Charts is a Seeking Alpha partner

DIVIDENDS

LONN.SW does not pay dividends or no data was received

iO Charts is a Seeking Alpha partner

iO Charts is a Seeking Alpha partner

VALUATION

Valuation Ratios

Loading...
Valuation Ratios data
Trailing P/E23.26
Price to OCF17.94
Price to FCF-
Price to EBITDA10.80
EV to EBITDA12.71

Valuation (Sales/Book Value)

Loading...
Valuation (Sales/Book Value) data
Price to Sales3.59
Price to Book4.25
EV to Sales4.23

iO Charts is a Seeking Alpha partner

iO Charts is a Seeking Alpha partner

FINANCIALS

Per share

Loading...
Per share data
Current share count72.12M
EPS (TTM)24.09
FCF per share (TTM)-5.76

Income statement

Loading...
Income statement data
Revenue (TTM)11.13B
Gross profit (TTM)3.59B
Operating income (TTM)2.05B
Net income (TTM)1.72B
EPS (TTM)24.09
EPS (1y forward)16.42

Margins

Loading...
Margins data
Gross margin (TTM)32.28%
Operating margin (TTM)18.46%
Profit margin (TTM)15.45%

Balance Sheet

Loading...
Please create a free account or log in to access this chart
Balance Sheet data
Cash1.40B
Net receivables1.55B
Total current assets5.33B
Goodwill2.85B
Intangible assets2.00B
Property, plant and equipment0.00
Total assets17.88B
Accounts payable0.00
Short/Current long term debt3.79B
Total current liabilities2.61B
Total liabilities8.47B
Shareholder's equity9.41B
Net tangible assets0.00

Cash flow

Loading...
Please create a free account or log in to access this chart
Cash flow data
Operating cash flow (TTM)2.23B
Capital expenditures (TTM)2.64B
Free cash flow (TTM)-411.00M
Dividends paid (TTM)605.25M

Financial returns

Loading...
Please create a free account or log in to access this chart
Financial returns data
Return on Equity18.26%
Return on Assets9.61%
Return on Invested Capital17.96%
Cash Return on Invested Capital-4.30%

iO Charts is a Seeking Alpha partner

iO Charts is a Seeking Alpha partner

STOCK INFORMATION

Stock chart

Loading...
Stock price data
Open549.00
Daily high557.40
Daily low547.00
Daily Volume175K
All-time high784.60
1y analyst estimate634.19
Beta0.64
EPS (TTM)24.09
Dividend per share-
Ex-div date13 May 2024
Next earnings date29 Jan 2025

Downside potential

Loading...
Downside potential data
LONN.SWS&P500
Current price drop from All-time high-29.34%-1.68%
Highest price drop-79.19%-56.47%
Date of highest drop4 Jun 20129 Mar 2009
Avg drop from high-26.30%-11.11%
Avg time to new high28 days12 days
Max time to new high1830 days1805 days

iO Charts is a Seeking Alpha partner

iO Charts is a Seeking Alpha partner

COMPANY DETAILS
LONN.SW (Lonza Group AG) company logo
Marketcap
39.98B
Marketcap category
Large-cap
Description
Lonza Group AG, together with its subsidiaries, supplies various products and services for pharmaceutical, biotech, and nutrition markets in Europe, North and Central America, Latin America, Asia, Australia, New Zealand, and internationally. It operates through Biologics, Small Molecules, Cell & Gene, and Capsules & Health Ingredients segments. The Biologics segment engages in the contract development and manufacturing of biopharmaceuticals for clinical and commercial manufacturing needs throughout the product lifecycle, including drug substance and drug product manufacturing. The Small Molecules segment operates as an integrated development and manufacturing service provider for small molecule drug substances and their intermediates. This segment also supports customers across various aspects of design, development, and manufacturing, including particle engineering and drug product packaging. The Cell & Gene segment develops technologies and platforms that industrialize the manufacturing processes and production of cell and gene therapies; offers contract development and manufacturing services, and regulatory support for a range of allogeneic and autologous cell therapies, and exosome-based therapies, as well as viral vector gene therapies. This segment also provides Cocoon platform, a closed automated system for patient-scale cell therapy manufacturing; and specialty raw materials and enabling technology solutions in cell and gene therapy, injectable drugs, vaccines, and bio-manufacturing markets. The Capsules & Health Ingredients segment offers capsules, dosage form solutions, and health ingredients for pharmaceutical and nutraceutical customers. Lonza Group AG was incorporated in 1897 and is headquartered in Basel, Switzerland.
Employees
17834
Investor relations
-
CEO
Country
Switzerland
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...

iO Charts is a Seeking Alpha partner

iO Charts is a Seeking Alpha partner

UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
All newsPress releases
No items found